MX2020003606A - Tratamiento del sindrome del cromosoma x fragil con canabidiol. - Google Patents

Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Info

Publication number
MX2020003606A
MX2020003606A MX2020003606A MX2020003606A MX2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A MX 2020003606 A MX2020003606 A MX 2020003606A
Authority
MX
Mexico
Prior art keywords
fragile
syndrome
cannabidiol
treatment
subject
Prior art date
Application number
MX2020003606A
Other languages
English (en)
Inventor
John Messenheimer
Nancy Tich
Donna Gutterman
Terri Sebree
Marcel Bonn-Miller
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2020003606A publication Critical patent/MX2020003606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente tecnología se refiere a un método de tratamiento de uno o más síntomas de conducta del síndrome del cromosoma X frágil en un sujeto, mediante la administración transdérmica de una cantidad eficaz de canabidiol (CBD) al sujeto, con lo que son tratados en el sujeto uno o más síntomas de conducta del síndrome del cromosoma X frágil.
MX2020003606A 2017-09-28 2018-09-27 Tratamiento del sindrome del cromosoma x fragil con canabidiol. MX2020003606A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564834P 2017-09-28 2017-09-28
US201862632532P 2018-02-20 2018-02-20
PCT/IB2018/057519 WO2019064234A1 (en) 2017-09-28 2018-09-27 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

Publications (1)

Publication Number Publication Date
MX2020003606A true MX2020003606A (es) 2020-10-28

Family

ID=63878731

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003606A MX2020003606A (es) 2017-09-28 2018-09-27 Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2022012424A MX2022012424A (es) 2017-09-28 2020-07-13 Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012424A MX2022012424A (es) 2017-09-28 2020-07-13 Tratamiento del sindrome del cromosoma x fragil con canabidiol.

Country Status (21)

Country Link
US (11) US10213390B1 (es)
EP (2) EP3687513B1 (es)
JP (3) JP7210564B2 (es)
KR (2) KR20220045070A (es)
AU (1) AU2018343256A1 (es)
BR (1) BR112020005918A2 (es)
CA (1) CA3077330A1 (es)
CY (1) CY1125071T1 (es)
DK (1) DK3687513T3 (es)
ES (1) ES2907325T3 (es)
HR (1) HRP20220277T1 (es)
HU (1) HUE058102T2 (es)
IL (1) IL273495A (es)
JO (1) JOP20200082A1 (es)
LT (1) LT3687513T (es)
MX (2) MX2020003606A (es)
PL (1) PL3687513T3 (es)
PT (1) PT3687513T (es)
RS (1) RS62969B1 (es)
SI (1) SI3687513T1 (es)
WO (1) WO2019064234A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058102T2 (hu) * 2017-09-28 2022-07-28 Zynerba Pharmaceuticals Inc Fragilis X szindróma és autizmus kezelése kannabidiollal
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
GB2589306A (en) * 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
WO2021158059A1 (ko) 2020-02-07 2021-08-12 건국대학교 글로컬산학협력단 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
EP4157236A1 (en) * 2020-05-26 2023-04-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
JP2023532880A (ja) * 2020-06-29 2023-08-01 ジナーバ・ファーマシューティカルズ・インコーポレイテッド カンナビジオールによる脆弱ｘ症候群の処置
EP4255402A1 (en) * 2020-12-03 2023-10-11 Zynerba Pharmaceuticals, Inc. Cannabidiol for the treatment of refractory seizures
WO2023070045A1 (en) * 2021-10-22 2023-04-27 Zynerba Pharmaceuticals, Inc. Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FI20020333A0 (fi) 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
WO2008060375A2 (en) * 2006-10-06 2008-05-22 The Regents Of The University Of Californina Upregulating bdnf levels to mitigate mental retardation
WO2009018389A1 (en) 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
PT2473475T (pt) 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
MX2015008766A (es) 2013-01-08 2016-03-07 Yissum Res Dev Co Compuestos cbd fluorados, composiciones y usos de los mismos.
CA2929321C (en) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
US11224660B2 (en) 2014-05-29 2022-01-18 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US20170224634A1 (en) 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
WO2015200864A1 (en) 2014-06-27 2015-12-30 Crowley Kenton L Buccal and sublingual cannabinoid formulations and method of making the same
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
CA2965493C (en) 2014-10-21 2021-12-07 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
US10716766B2 (en) * 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
US20190060300A1 (en) 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
WO2017158539A1 (en) 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
GB2549278B (en) 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
US11839601B2 (en) 2016-04-19 2023-12-12 Canna-B Cure Ltd Cannabis-enriched enzymatically treated therapeutic composition
CN109789090A (zh) 2016-06-02 2019-05-21 阿克罗斯实验室公司 大麻素的半固体和粘性液体鼻腔配制品
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
HUE058102T2 (hu) 2017-09-28 2022-07-28 Zynerba Pharmaceuticals Inc Fragilis X szindróma és autizmus kezelése kannabidiollal
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
EP4157236A1 (en) 2020-05-26 2023-04-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
JP2023532880A (ja) 2020-06-29 2023-08-01 ジナーバ・ファーマシューティカルズ・インコーポレイテッド カンナビジオールによる脆弱ｘ症候群の処置

Also Published As

Publication number Publication date
RS62969B1 (sr) 2022-03-31
KR20200058513A (ko) 2020-05-27
BR112020005918A2 (pt) 2020-10-06
US20190167605A1 (en) 2019-06-06
JP2020535190A (ja) 2020-12-03
JP2022064988A (ja) 2022-04-26
US20230414533A1 (en) 2023-12-28
JOP20200082A1 (ar) 2020-04-30
SI3687513T1 (sl) 2022-04-29
JP7210564B2 (ja) 2023-01-23
EP3967301A1 (en) 2022-03-16
US20190117588A1 (en) 2019-04-25
PT3687513T (pt) 2022-03-01
US20190262280A1 (en) 2019-08-29
US20220096396A1 (en) 2022-03-31
CA3077330A1 (en) 2019-04-04
EP3687513A1 (en) 2020-08-05
US20200360299A1 (en) 2020-11-19
KR20220045070A (ko) 2022-04-12
US20200030255A1 (en) 2020-01-30
US20230000790A1 (en) 2023-01-05
US10213390B1 (en) 2019-02-26
CY1125071T1 (el) 2023-06-09
US10758497B2 (en) 2020-09-01
AU2018343256A1 (en) 2020-04-02
PL3687513T3 (pl) 2022-04-19
ES2907325T3 (es) 2022-04-22
JP2023040166A (ja) 2023-03-22
EP3687513B1 (en) 2021-12-15
WO2019064234A1 (en) 2019-04-04
US11458110B2 (en) 2022-10-04
HUE058102T2 (hu) 2022-07-28
US10314792B2 (en) 2019-06-11
US11779549B2 (en) 2023-10-10
IL273495A (en) 2020-05-31
US20200214995A1 (en) 2020-07-09
DK3687513T3 (da) 2022-03-07
LT3687513T (lt) 2022-03-10
MX2022012424A (es) 2022-11-30
US10568848B2 (en) 2020-02-25
HRP20220277T1 (hr) 2022-05-13
US20230364028A1 (en) 2023-11-16
US10471022B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
MX2020003606A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
CL2018003213A1 (es) Inhibidores enzimáticos.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
EA201591761A1 (ru) Композиции на основе наночастиц
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
BR112017006113A2 (pt) combinações sinérgicas de auristatina
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
NI201700057A (es) Método para tratar, prevenir o reducir el riesgo de infección cutánea
AR112405A1 (es) Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
BR112016012248A2 (pt) método de tratamento de nefropatia
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
AR095483A1 (es) Composición y método para prevenir, reducir, aliviar o tratar el vómito idiopático
MX2020001769A (es) Composiciones y metodos para inhibir patogenos de plantas.
MX2016007224A (es) Vacuna contra el circovirus porcino tipo 2.
CL2012003202A1 (es) Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.
BR112016014099A2 (pt) método de tratamento de feridas
BR112017005532A2 (pt) acionamento por correia com extensão de compressão
BR112015023260A2 (pt) método de tratamento de grão com ozônio
EA201690445A1 (ru) Лечение рака
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.